Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2012-09-30
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Embryo selection based on morphology and degree of development is not sufficient to identify chromosomally normal embryo.
The experience gained in the last 10 years with PGS using FISH technique has concluded that it has no clinical value even in selected populations of advanced maternal age, repeated failure in IVF/ICSI, recurrent abortion or severe male factor. The three main arguments were: 1)the limitation of the technique to enumerate the 24 chromosomes, 2)the reduced ability of implantation after biopsy performed on the third day of the in vitro development and 3)the discarding of embryos that could have been self-corrected.
The possibility of amplifying the entire genome from one or two cells of the embryo permits the use of methodologies for the screening of 24 chromosomes, such as, comparative genomic hybridization-performed on metaphase plates (mCGH) or on slides with thousands of probes corresponding to human chromosome segments cloned in bacteria (BAC array) or array of single nucleotide polymorphisms (aSNP), besides the classic or real time qPCR.
Other important developments include the culture of pre-embryos to the blastocyst stage. This allows more cells to be obtained and studied when hatching the trophectoderm, and the efficiency achieved with the vitrification allows the transfer in another cycle, unstimulated, with better results than fresh transfer. These last two facts are important, the first from a practical point of view because the study is performed on an embryo that has reached the highest degree of development in vitro, and the second because the receptivity of the endometrium is better in an unstimulated cycle, and also it avoids the potential iatrogenic effect of the drugs used in ovarian stimulation cycle. On this last point, it is interesting that the finding reported by the last Australian Register about the risk of birth defects after reproductive technologies, show that the rate of abnormalities of the thawed embryos is not different from those born without reproductive technology, while the rate of birth anomalies with fresh embryos transfer is greater than those without assisted reproductive technologies. Furthermore, the non embryo transfer in the fresh cycle permits more time for study and implementation of different genetic methodologies that previously could not be performed due to time constraints. This new option allows us to organize the work better and obviously gain greater efficiency. This possibility is very important to geneticists who are willing to work every day when necessary. Considering the above mentioned arguments, we propose to perform on couples that require IVF/ICSI the embryo biopsy at the blastocyst stage, the immediate vitrification thereof, and to transfer the best blastocyst, evaluated by its expansion and the quality of the trophectoderm and inner cell mass, in a subsequent cycle with physiologically primed endometrium. The molecular karyotype (aCGH) will be performed after the embryo transfer. The result of the karyotype of embryos transferred will be determined when the patient take the pregnancy test. In this way, we will know the proportion and type of chromosomal abnormalities in three groups of patients after blastocyst transfer: a) those that could not get pregnant, b) those that got pregnant but miscarried and c) those that successfully gave birth. We suggest that this trial design will allow further clarification of the biological behavior of preimplantational aneuploidies and to assess whether it really has clinical value. If preimplantation chromosome abnormalities have clinical value, the proportion and types of aneuploidies should be different in the three groups of patients mentioned above.
We will offer free to all pregnant women the amniocentesis to confirm whether the fetal karyotype is consistent with the trophectoderm, especially those who have had an aneuploid blastocyst transfer. Those who refuse to be assessed prenatally, testing will be made at the time of delivery via umbilical cord blood. In contrast, the patients who have miscarried, depending on the gestational age, will be offered a study of the aborted product obtained by curettage, chorionic villus puncture, amniocentesis or fetal biopsy.
The patients who did not achieve pregnancy or who lost it spontaneously due to chromosome abnormality, can benefit in a subsequent transfer with the remaining vitrified euploid embryos or with those obtained during a new stimulation cycle performing the aCGH before transfer. Patients who achieved "take home a baby" and who decide to have more children may also take advantage of the remaining euploid devitrified blastocyst.
We prefer in this clinical trial not to transfer during the stimulated cycle because a pilot study, with unstimulated cycle transfer, yielded better results in terms of pregnancy rate compared to historical data of PGD with fresh transfer. Other recent studies of devitrified blastocyst transfer in a natural cycle or with endometrium physiologically prepared also show better pregnancy rates and besides, are less iatrogenic than the fresh embryo transfer.
The hypothesis of embryonic aneuploidy screening for selecting the best embryo is correct and is supported by the published data of cytogenetic studies on gametes and/or human embryos. When the couple produce enough blastocysts of good quality, the selection of the euploid blastocyst for transfer is beneficial, but if the couple produce only one aneuploid blastocyst we are not sure of discarding it until we are able to demonstrate the behavior of aneuploidies in preimplantational period, especially if the chromosomal abnormality found is not part of the pathology of the newborn, otherwise we would be eliminating the last chance for the couple to become genetic parents.
We believe that once demonstrated, the clinical value of the embryo molecular karyotype and its application, could be beneficial in achieving a better ongoing pregnancy rate in selected patient groups such as women of advanced reproductive age, recurrent abortions and severe male factor.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Molecular blastocyst karyotype
Trophectoderm biopsy for genetic study by aCGH
Trophectoderm biopsy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trophectoderm biopsy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. ≥ 21 years of age
3. Regular menstrual cycles every 27-35 days
4. BMI less than 35
5. Normal levels of FSH, LH and E2 in early follicular phase
6. Antral follicles count ≥ 6
7. Couple Normal karyotype
8. Expansion of the triplet CGG of FMR1 gene ≤ 45 repetitions
9. Pelvic transvaginal ultrasound no more than one year prior to oocyte retrieval
10. Normal Hysterosalpingography made not more than 3 years prior to oocyte retrieval
11. Normal Pap and breast exam no more than one year old
12. Negative serology for HIV, hepatitis B and C
13. Positive serology for Rubella and Varicella
14. Administration of 1 mg folic acid / d in both partners from two to three months prior to the procedure
15. Woman has had previous cycles of ovarian stimulation, requires a wash out period of 30 days.
16. Patients must agree with the clinical trial and sign the informed consent which explains free participation in the project
17. Patients can abandon participation in the project at any time.
Exclusion Criteria
2. Endometriosis grade III and IV
3. Unilateral or bilateral Hydrosalpinx
4. Previous cycles of IVF with poor response to ovarian stimulation (≤ 5 oocytes) or excessive response (OHSS)
5. Azoospermia with TESA or TESE requiring
6. Allergy to any of the drugs used in the procedure
7. Carriers of genetic or chromosomal diseases
8. Repeated IVF failures (≥ 5 cycles)
9. Simultaneous participation in another clinical trial
21 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fecunditas Instituto de Medicina Reproductiva
UNKNOWN
Hospital del Mar
OTHER
Red Latinoamericana de Reproducción Asistida
UNKNOWN
University of Buenos Aires
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Roberto Coco
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roberto Coco, PhD
Role: STUDY_DIRECTOR
UBA
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fecunditas Reproductive Medicine Institute
Buenos Aires, Buenos Aires, Argentina
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Roberto Coco, PhD
Role: primary
Maria E Ducatelli, PhD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Funsare - 001
Identifier Type: -
Identifier Source: org_study_id